921 related articles for article (PubMed ID: 16105155)
1. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
2. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
[TBL] [Abstract][Full Text] [Related]
3. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
4. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
5. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
[TBL] [Abstract][Full Text] [Related]
6. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
7. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche A; Schweitzer MA; Häring HU;
Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
[TBL] [Abstract][Full Text] [Related]
8. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
9. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
Home PD; Rosskamp R; Forjanic-Klapproth J; Dressler A;
Diabetes Metab Res Rev; 2005; 21(6):545-53. PubMed ID: 16021649
[TBL] [Abstract][Full Text] [Related]
10. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
Warren E; Weatherley-Jones E; Chilcott J; Beverley C
Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
[TBL] [Abstract][Full Text] [Related]
12. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
[TBL] [Abstract][Full Text] [Related]
13. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin.
Herwig J; Scholl-Schilling G; Böhles H
J Pediatr Endocrinol Metab; 2007 Apr; 20(4):517-25. PubMed ID: 17550216
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
Yki-Järvinen H; Kauppinen-Mäkelin R; Tiikkainen M; Vähätalo M; Virtamo H; Nikkilä K; Tulokas T; Hulme S; Hardy K; McNulty S; Hänninen J; Levänen H; Lahdenperä S; Lehtonen R; Ryysy L
Diabetologia; 2006 Mar; 49(3):442-51. PubMed ID: 16456680
[TBL] [Abstract][Full Text] [Related]
16. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
17. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
18. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
19. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
Ratner RE; Hirsch IB; Neifing JL; Garg SK; Mecca TE; Wilson CA
Diabetes Care; 2000 May; 23(5):639-43. PubMed ID: 10834423
[TBL] [Abstract][Full Text] [Related]
20. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
